Tuberculosis (TB) is a global burden with one –third of the world’s population infected with the pathogen Mycobacterium tuberculosis complex and annually 1.4 million deaths occur due to the disease. This high incidence of infection and the increased rate of multi-drug resistant and extensively-drug resistant strains of the organism further complicated the problem of TB control and have called for an urgent need to develop new anti-TB drugs from plants. In this study, the in vitro activity of root of Calpurnia aurea, seeds of Ocimum basilicum, leaves of Artemisia abyssinica, Croton macrostachyus, and Eucalyptus camaldulensis were evaluated against M. tuberculosis and M. bovis strains.
Visceral leishmaniasis (VL) is a vector-borne protozoan neglected tropical disease. In some parts of Ethiopia, it is a public health problem and its main causative agent is the Leishmania donovani complex. The objective of the study was to determine the seroprevalence of VL and factors associated among the asymptomatic pastoral community of Dire District, Borena Zone, Oromia Region, Ethiopia. A community-based study was conducted among 432 pastoralist communities from June to July 2021. A systematic random sampling method was used to select households. Pretested structured questionnaires and face-to-face interviews were used to collect data. A single finger-prick blood sample was collected and tested for Leishmania donovani complex using an immune-chromatographic test (rk39-ICT). A logistic regression model was used to assess factors associated with VL infection and a p-value of < 0.05 was considered statistically significant. A total of 432 study participants were included (their mean age was 26.69) and 218 (50.5%) were females. The overall seroprevalence of VL was 33/432(7.6%) (95%CI: 5.32–15.60). Sero-prevalence was significantly associated with high family size (>5) (adjusted odds ratios (AOR) = 5.134; 95% CI: 2.032–9.748), sleeping or/and staying under acacia tree (AOR = 2.984; 95%CI = 1.074–8.288), presence of cracked house walls (AOR = 1.801; 95%CI: 1.026–4.926), presence of termite hills (AOR = 1.938; 95%CL: 1.002–7.050), availability of water points (AOR = 3.893; 95%CI: 1.034–7.426) and presence of domestic animals (AOR = 2.124; 95% CI: 2.341–5.108). It is recommended that community awareness on the transmission and prevention methods of Leishmania donovani complex and taking appropriate interventions on the identified factors play a greater role to prevent and control infection in the area. Further investigation is also needed to characterize the pathogens and risk factors and tackle the problem.
There have been limited studies linking baseline factors, including the viral load (VL) test, with virological non-suppression since the introduction of dolutegravir (DTG)-based regimens as first-line antiretroviral treatment (ART) in Ethiopia. This study aimed to identify baseline factors associated with virological non-suppression between October 2020 and July 2022. A follow-up study was conducted in eastern Ethiopia among newly diagnosed people living with HIV (PLHIV). A questionnaire and a checklist were used to collect the data. Five milliliters of venous blood were obtained at baseline and six months to determine the VL. A VL test was performed using the Abbott RealTime HIV-1 assay. To determine predictors of virological non-suppression, bivariate and multivariate logistic regression analyses were used. There were 235 PLHIV enrolled, 70.6% of whom were female, with a mean age of 33.9 years. Of the 161 retained on ART, virological non-suppression was 8.7% at six months. Baseline predictors of virological non-suppression were age ≤ 30 years, a history of substance use, and a VL greater than 4-log10 copies/mL. In this cohort, virological non-suppression was found to be optimal but still lagged slightly behind the third 95%–target. Thus, targeted interventions, the introduction of baseline VL testing to improve treatment outcomes, and fostering the attainment of UNAIDS 95–95–95 targets are recommended. Furthermore, broader research is recommended to explore the reasons for virological non-suppression in the study area.
Background: Loss to follow-up (LTFU) and death are unfavorable outcomes of human immunodeficiency virus (HIV) treatment. This study aimed to identify the predictors of LTFU and death among individuals with newly diagnosed HIV receiving dolutegravir (DTG)–based first-line antiretroviral treatment (ART) in eastern Ethiopia. Methods: A multisite prospective cohort study was carried out between October 2020 and July 2022. New case patients who started ART were enrolled consecutively and then followed up for the next 6 months. A structured questionnaire and checklists were used to collect data. HIV viral load was determined using the Abbott RealTime HIV-1 assay. Bivariable and multivariable logistic regression models were used to identify baseline factors associated with the outcomes. Results: A total of 235 people with newly diagnosed HIV were enrolled; 16.6% (95% confidence interval, 12.3%–21.9%) were lost to follow-up, and 5.9% (3.5%–9.8%) died within 6 months of follow-up. Baseline World Health Organization clinical stage I (adjusted odds ratio, 3.93 [95% confidence interval, 1.34–11.57]), low viral load (3.67 [1.09–12.36]), and body weight (1.04 [1.01–1.07]) were predictors of LTFU, whereas nonfunctional status (10.02 [1.9–51.3]) was the only factor associated with death. Conclusions: LTFU and death rates among patients with DTG were relatively high, accounting for roughly a quarter of the attrition of people with newly diagnosed HIV from ART care and services. Thus, targeted interventions are required to reduce LTFU and death among individuals with HIV on ART. Further investigation is necessary to evaluate the long-term effects of DTG-based regimens on LTFU and its impact on HIV mortality rates, and qualitative research, specifically tracing LTFU, is recommended.
Background and Aims: In Ethiopia, HIV‐1 pretreatment drug resistance (PDR) data are limited owing to a lack of routine genotyping resistance tests. This study aimed to determine the prevalence of HIV‐1 PDR mutations and genetic diversity among newly diagnosed people with HIV in eastern Ethiopia.Methods: HIV RNA was extracted using Abbott m2000sp. HIV‐1 partial pol genes were amplified and sequenced using the Sanger dideoxy method. DRM profiles were examined and interpreted according to the calibrated population resistance (CPR) and Stanford University HIV drug resistance algorithms. A maximum likelihood phylogenetic tree was constructed using PhyML version 3.0 and visualized using the iTOL tool. Bivariable and multivariable logistic regression models were used to identify baseline factors associated with outcomes at a p value of < 0.05.Results: Among newly diagnosed individuals with baseline viral load (≥ 1000 copies/mL) and amplifications were successful, the genotyping success rate was 78.4%. Among the isolates successfully sequenced, three HIV‐1 strains were detected, of which 97.1% had HIV‐1 subtype C, 1.4% A1C, and 1.4% CF1 recombinant. According to the Stanford HIVDR algorithm, 21.7% of people had at least one drug associated PDR mutation, whereas CPR reported 14.5% DRMs. NNRTIs had the highest PDR mutation rate (13.0%), followed by NRTIs (7.2%) and PIs (2.9%). The most commonly observed major DRMs were: NNRTIs (K103N and G190A), NRTIs (D67G and L210W), and PIs (L90M and I54S). Patients who were bedridden at enrollment were more likely to harbor PDR mutations (AOR: 5.4; 95% CI: 1.53–30.7).Conclusions: High PDR levels, predominantly for NNRTIs, are observed. During clinical follow‐up, special attention should be given to bedridden functional status patients. Further surveillance studies are needed to evaluate the long‐term effects of prolonged accumulation of resistance and its transmission on current ART regimens and to design appropriate interventions to halt the HIV epidemic.